



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/659,199	09/10/2003	Stephen M. Allen	BB1157 US CNT	5569
26691	7590	12/03/2008	EXAMINER	
POTTER ANDERSON & CORROON LLP			KUBELIK, ANNE R	
ATTN: KATHLEEN W. GEIGER, ESQ.				
P.O. BOX 951			ART UNIT	PAPER NUMBER
WILMINGTON, DE 19899-0951			1638	
			MAIL DATE	DELIVERY MODE
			12/03/2008	PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/659,199	ALLEN ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Anne R. Kubelik	1638	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

1) Responsive to communication(s) filed on 15 September 2008.

2a) This action is **FINAL**.                  2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

4) Claim(s) 26-29 is/are pending in the application.

4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.

5) Claim(s) \_\_\_\_\_ is/are allowed.

6) Claim(s) 26-29 is/are rejected.

7) Claim(s) \_\_\_\_\_ is/are objected to.

8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All    b) Some \* c) None of:

1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

1) <input type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date. _____ .
3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date _____ .	5) <input type="checkbox"/> Notice of Informal Patent Application
	6) <input type="checkbox"/> Other: _____ .

**DETAILED ACTION**

1. Claims 26-29 are pending.
2. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

***Claim Rejections - 35 USC § 112***

3. Claims 26-29 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for nucleic acids encoding a SEQ ID NO:18 and constructs and vectors comprising them, does not reasonably provide enablement for nucleic acids encoding a protein with 90% identity to SEQ ID NO:18 and constructs and vectors comprising them. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims. The rejection is repeated for the reasons of record as set forth in the Office action mailed 27 May 2008. Applicant's arguments filed 15 September 2008 have been fully considered but they are not persuasive.

The claims are broadly drawn to nucleic acids encoding a protein with 90% or 95% identity to SEQ ID NO:18 and constructs and vectors comprising them.

The instant specification, however, only provides guidance for cDNA libraries from a number of plants and plant tissues, including wheat developing kernel, and sequencing the inserts from an unknown number of the clones in these libraries (example 1), BLAST analysis of the cDNA sequences (example 2), identification of clones that have homology to the *Arabidopsis*, potato and corn brittle-1 homologs; the clones include SEQ ID NO:17, which

encodes SEQ ID NO:18 (example 3). The specification also provides general guidance for the expression of chimeric genes in monocots (example 4), dicots (example 5), and microbes (example 6).

The instant specification fails to provide guidance for which amino acids of SEQ ID NO:18 can be altered and to which other amino acids, and which amino acids must not be changed, to maintain adenylate translocator activity of the encoded protein. The specification also fails to provide guidance for which amino acids can be deleted and which regions of the protein can tolerate insertions and still produce a functional enzyme.

Nucleic acids encoding proteins with 90% identity to the 433 amino acid long SEQ ID NO:18 would encode proteins with 43 amino acid substitutions, and nucleic acids encoding proteins with 95% identity to SEQ ID NO:18 would encode proteins with 21 amino acid substitutions. The instant specification fails to provide guidance for how to make these nucleic acids.

The sensitivity of proteins to alterations in even a single amino acid in a sequence is exemplified by Lazar et al (1988, Mol. Cell. Biol. 8:1247-1252), who teach that a replacement of aspartic acid at position 47 with alanine or asparagine in transforming growth factor alpha had no effect, but that replacement with serine or glutamic acid sharply reduced biological activity (see the abstract). Similarly, Hill et al (1998, Biochem. Biophys. Res. Comm. 244:573-577) teach that when three histidines that are maintained in ADP-glucose pyrophosphorylase across several species are substituted with the “nonconservative” amino acid glutamine, there is little effect on enzyme activity, while the substitution of one of those histidines with the “conservative” amino

acid arginine drastically reduced enzyme activity (see Table 1). All these mutated proteins, however, would have at least 95% identity to the original protein.

Guo et al (2004, Proc. Natl. Acad. Sci. USA 101: 9205-9210) teach that while proteins are fairly tolerant to mutations resulting in single amino acid changes, increasing the number of substitutions additively increases the probability that the protein will be inactivated (pg 9209, right column, paragraph 2).

The specification fails to provide an assay for Brittle-1 activity. The specification on pg 6, lines 20-21, references Shannon et al (1998, Plant Physiol. 117:1235-1252). In this reference, ADP-glucose uptake was measured in isolated amyloplasts from *bt-1* mutants (See paragraph spanning pg 1245-1246). The specification fails to teach how to use this method to assay variant nucleic acids. It is possible Applicant envisions transforming *bt-1* mutant maize or a yet unidentified wheat equivalent with nucleic acids encoding the variants, isolating the amyloplasts from the transformants, and measuring ADP-glucose uptake. However, it is not clear that this laborious process would even be possible. Sullivan et al (1995, Planta 196:477-484) teach that the full-length maize Brittle-1 coding region could not be expressed in *E. coli* (pg 478, left column, paragraph 3).

Thus, making and analyzing proteins with up to 43 amino acid substitutions that also have adenylate translocator activity would require undue experimentation.

Given the claim breadth, unpredictability in the art, undue experimentation, and lack of guidance in the specification as discussed above, the instant invention is not enabled throughout the full scope of the claims.

Applicant urges that they incorporate their previous arguments (response pg 2).

This is not found persuasive. The previous responses are incorporated.

Applicant urges that it is not clear what part of the rejection was modified (response pg 2).

This is not found persuasive. The paragraphs about the numbers of nucleic acids encompassed by the claims and about assaying the protein were modified.

4. Claims 26-29 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter that was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The rejection is repeated for the reasons of record as set forth in the Office action mailed 27 May 2008. Applicant's arguments filed 15 September 2008 have been fully considered but they are not persuasive.

The claims are broadly drawn to a multitude of nucleic acids that encode brittle-1 proteins with 90% identity to SEQ ID NO:18. In contrast, the specification only describes a coding sequence from wheat that comprises SEQ ID NO:17. Applicant does not describe other nucleic acids encompassed by the claims, and the structural and functional features that distinguish all such nucleic acids from other nucleic acids are not provided.

Hence, Applicant has not, in fact, described nucleic acids that encode a protein with 90% identity to SEQ ID NO:18 within the full scope of the claims, and the specification fails to provide an adequate written description of the claimed invention.

Therefore, given the lack of written description in the specification with regard to the structural and functional characteristics of the claimed compositions, it is not clear that Applicant was in possession of the claimed genus at the time this application was filed.

Applicant urges that they incorporate their previous arguments (response pg 2).

This is not found persuasive. The previous responses are incorporated.

***Claim Rejections - 35 USC § 103***

5. Claims 26-29 rejected under 35 U.S.C. 103(a) as being unpatentable over Sullivan et al (1991, Plant cell 3:1337-1348) in view of Li et al (1992, J. Biol. Chem. 267:18999-19004). The rejection is repeated for the reasons of record as set forth in the Office action mailed 27 May 2008. Applicant's arguments filed 15 September 2008 have been fully considered but they are not persuasive.

The claims are broadly drawn to nucleic acids encoding a protein with 90% or 95% identity to SEQ ID NO:18 and expression constructs and vectors comprising them.

Sullivan et al teach the isolation of a vector comprising a genomic nucleic acid encoding the maize Brittle-1 protein (pg 1338, right column, paragraph 1, to pg 1339, right column, paragraph 1). Sullivan et al do not teach nucleic acids that encode brittle-1 proteins with 90% or 95% identity to SEQ ID NO:18.

At the time the invention was made, it would have been obvious to one of ordinary skill in the art to use the sequence taught by Sullivan et al to isolate brittle-1 homologs from other plants, including wheat, using the maize sequence as a probe, thus isolating a nucleic acid encoding a protein with 90% or 95% identity to SEQ ID NO: 18. A sequence comparison

between the maize nucleic acid sequence and the wheat sequence is provided; the regions of identity between the two nucleic acids indicate that such a hybridization would have been successful. One of ordinary skill in the art would have been motivated to do so to better study starch synthesis in endosperm and to study the function of brittle-1. Further, because Li et al teach that brittle-1 has a transit peptide that targets the protein to the inner amyloplast membrane, one of ordinary skill in the art would have been motivated to isolate the wheat homolog to increase the repertoire of such transit peptides to use in expression constructs in plant transformation.

Applicant urges that Sullivan does not teach the claimed invention (response pg 3).

This is not found persuasive. In response to applicant's arguments against the references individually, one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See *In re Keller*, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); *In re Merck & Co.*, 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986).

Applicant urges that the availability of transit peptides in plants such as wheat is well-known in the art, citing Smith; thus, one of skill in the art would have no motivation to increase this repertoire (response pg 3).

This is not found persuasive because one of ordinary skill in the art would have been motivated to do so to better study starch synthesis in endosperm and to study the function of brittle-1. Further, the known existence of a few wheat transit peptides does not mean that others are not desirable, especially as each would target to different chloroplast membranes.

***Conclusion***

6. **THIS ACTION IS MADE FINAL.** See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anne R. Kubelik, Ph.D., whose telephone number is (571) 272-0801. The examiner can normally be reached Monday through Friday, 8:30 am - 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anne Marie Grunberg, can be reached at (571) 272-0975.

The central fax number for official correspondence is (571) 273-8300.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

December 3, 2008

/Anne R. Kubelik/  
Primary Examiner, Art Unit 1638